AMAL THERAPEUTICS
AMAL Therapeutics SA is a spin-off from the University of Geneva active in cancer immunotherapy. AMAL has developed a unique protein-based immunization platform providing activation signal to dendritic cells simultaneously to priming both helper and killer cells for various antigens and HLA restrictions. This first-in-class platform is offering the opportunity to develop standardized and indication-tailored active immunotherapies.
